Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rankning i aktier #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aktiekurs
$0.00023723
Senast synkroniserad: 2024-08-26
Marknadsvärde
$1.41K
Förändring (1 dag)
111.67%
Förändring (1 år)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Kategori

P/S-tal för Pharnext S.A. (ALPHA)
P/S-tal per August 2026 TTM: 0.12
Enligt Pharnext S.A. senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0.12. I slutet av 2022 hade företaget ett P/S-tal på 17.807T.
Historik för P/S-tal för Pharnext S.A. från 2012 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
2026 (TTM) 0.12 -99.84%
2023 73.60 -100.00%
2022 17.807T -99.54%
2021 3.91Qa -97.44%
2020 152.45Qa 270.01%
2019 41.20Qa 1,356.30%
2018 2.83Qa -40.90%
2017 4.79Qa 24.33%
2016 3.85Qa -46.55%
2015 7.20Qa 4.78%
2014 6.87Qa -4.45%
2013 7.19Qa 0.00%
2012 0.00 0.00%
P/S-tal för liknande företag eller konkurrenter
Företag P/S-tal Skillnad i P/S-tal Land
9.88 8,203.19%
US
10.30 8,557.98%
NL
- -
CH
4.98 4,084.29%
BE
- -
KR